AntlerA antibody drug for treatment of vascular retinopathies

SAN FRANCISCO: SAN FRANCISCO, June 9, 2021 /PRNewswire/ -- AntlerA has applied its next generation programmable ANT platform to develop therapeutics for treating retinopathies. Blood vessels that supply oxygen and nutrients to the retina are tightly sealed to ensure that they do not leak their contents into the retina. Retinopathy...

Click to view original post